Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indatuximab Ravtansine with Len/Dex or Pom/Dex in RRMM
NCT01638936Phase 2Completed
- Sponsor
- Biotest AG
- Start
- Jul 2012
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of indatuximab ravtansine in multiple myeloma (MM), sponsored by Biotest AG. Started Jul 2012; status: completed.
02
Drugs
indatuximab ravtansine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01638936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01638936.